Signal Breakdown
4 verified publisher articles from recent coverage.
1 verified Internet Archive TV segments.
7 verified related videos from the past week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- INTerpath-001 Phase 3 showed intismeran plus pembrolizumab cut recurrence risk by 42% in high‑risk melanoma patients.
- The trial also significantly improved distant metastasis‑free survival versus Keytruda alone.
- NEJM accepted the Phase 3 publication, providing strong clinical validation of the results.
Risk Factors
- A leaked data report prompted a sharp selloff, with multiple outlets noting roughly a 20% one‑day decline in the shares.
- Analysts and commentators warned the stock may already price in significant future sales, implying limited near‑term upside.
- Positive data raised manufacturing and scaling challenges that could strain Moderna's ability to meet demand.
Evidence
- 2026-10-25Source: TIINGO
Summary: Moderna shares have risen roughly 7x over the past year; a recent pullback and leaked melanoma vaccine trial data raise concerns that the stock may already price in significant future sales, implying limited upside.
Bearish - 2026-10-24Source: TIINGO
Summary: INTerpath-001 Phase 3: Moderna’s individualized neoantigen therapy intismeran plus Merck’s pembrolizumab cut recurrence risk by 42% in resected high‑risk melanoma, meeting the primary relapse‑free survival endpoint and a key secondary endpoint.
Bullish - 2026-10-24Source: TIINGO
Summary: Phase 3 data show intismeran (Moderna/Merck) plus Keytruda significantly improved recurrence-free and distant metastasis-free survival versus Keytruda alone; NEJM accepted the publication — strong clinical signal but raises manufacturing/scaling challenges for Moderna.
Bullish - 2026-10-24Source: GDELT
Summary: Oncologists praised melanoma data, but those results caused Moderna’s shares to tank, indicating a negative market reaction with adverse implications for Moderna’s oncology prospects.
Bearish
Showing 4 of 4 verified news articles
- Archive TV
Summary: A Moderna meltdown: shares tumbled after a data leak on its new drug, prompting a sharp stock drop and investor concern about the company's drug program and broader health-care sector impact.
Bearish
Showing 1 of 1 verified Archive TV segments
Summary: Reports that melanoma clinical data caused Moderna’s shares to drop, indicating negative investor reaction to its trial results.
BearishSummary: Moderna stock fell about 20% after a leak showed its cancer vaccine results were positive but underwhelming, with analysts citing inflated expectations and discussing options strategies.
BearishSummary: Moderna is briefly mentioned in a premarket snapshot about a 'leak' news item; the video is a short, multi-stock roundup rather than in-depth Moderna coverage.
NeutralSummary: CNBC reports Moderna’s new melanoma vaccine data is promising, calling it good news for melanoma treatment.
BullishSummary: Moderna is discussed after mixed trial results for its personalized melanoma vaccine (with Merck) — clinically positive reductions in recurrence but prompting a stock selloff.
BearishSummary: Moderna’s melanoma vaccine data disappointed investors—vaccine showed efficacy but results weren’t spectacular, causing the stock to plummet.
BearishSummary: Moderna plunged after leaked cancer vaccine data, becoming the S&P 500's worst performer and driving a sharp negative market reaction.
Bearish
Showing 7 of 7 verified videos
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.